Latest news with #BoehringerIngelheim
Globe and Mail
an hour ago
- Health
- Globe and Mail
Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. In June 2025, Zomagen Biosciences Ltd. conducted a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. In June 2025, Boehringer Ingelheim organized a study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. In June 2025, Novo Nordisk A/S announced a study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. In June 2025, Hanmi Pharmaceutical Company Limited conducted a phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Powys County Times
6 hours ago
- Health
- Powys County Times
Rules for cattle relaxed in the new Bluetongue rules
Cattle moving from England into Wales WILL be permitted if they are vaccinated for bluetongue, the Welsh Government says - but sheep must still be tested before crossing the border. In a new announcement on Friday, the Welsh Government confirmed it will allow cattle fully vaccinated with Boehringer Ingelheim's Bultavo-3 vaccine, to move under licence, from a Restricted Zone to Wales without a pre-movement test – however this will not apply to sheep. There has been outrage amongst Powys farmers about rules being brought in from July 1 which would mean that any sheep that crossed the Welsh border would require a test for the bluetongue virus. Tests for Bluetongue cost anywhere from £40-£70 per animal meaning some farmers would be faced with bills of tens of thousands to move livestock across the border for grazing or for going to market. The Welsh Government confirmed that 'all sheep must be pre-movement tested and require an accompanying licence to move into Wales to live from the Restricted Zone (RZ) in England, as no vaccine products currently meet the requirements for protecting sheep from BTV-3 to allow them to move out of the RZ.' Deputy First Minister with responsibility for Climate Change and Rural Affairs, Huw Irranca-Davies, said: 'My goal at this stage remains to keep Bluetongue out of Wales for the benefit of our animals and those who keep them. 'The economic and farmer wellbeing concerns caused by dealing with severe Bluetongue are first and foremost in my mind. "I also want to allow more time to observe the severity of the disease in England, and for keepers to vaccinate their herds and flocks. Help support trusted local news Sign up for a digital subscription now: As a digital subscriber you will get Unlimited access to the Oswestry Advertizer website Advert-light access Reader rewards 'I have made clear the thinking behind my decision in the Senedd this week, but I want to keep it under review. Should the evidence change, and we need to alter the policy, we will revisit and review this in a dynamic way. 'Our shared priority over the coming weeks is to promote vaccine take-up. All representatives at the Roundtable I recently convened were unanimous in their support for vaccination as the best method of protecting livestock and reducing the impacts of Bluetongue." 'I cannot in all conscience invite Bluetongue into Wales, but we are prepared to adapt to the evolving disease situation.' In the announcement, the Welsh Government also confirmed that as a response to increased risk of Bluetongue, including 'temperatures that are consistent with the active transmission period,' these measures will come into force as of today (June 20) in relation to the current Restricted Zone in England, which covers the east of England.
Nikkei Asia
17 hours ago
- Business
- Nikkei Asia
German drugmaker Boehringer eyes Japan as Asia hub with $346m investment
TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base for Asia and Oceania. The plant, in the country's northeastern prefecture of Yamagata, currently produces the diabetes and kidney disease treatment drug Jardiance, mainly for the domestic market.
Associated Press
a day ago
- Health
- Associated Press
Stop Rabies To Save Lives: Boehringer Ingelheim's Contribution to Rabies Elimination
Every nine minutes, rabies claims a life. Each year, this deadly virus steals nearly 60,000 lives, despite being entirely preventable through vaccination. Judith Masika from Kenya experienced this firsthand: Her husband died, due to a bite by a rabid dog. A tragedy that could have been prevented had there been better awareness. Eliminating rabies requires a global effort and strong collaboration. Boehringer Ingelheim is working to help prevent these tragic stories through our Stop Rabies program. The program focuses on a holistic approach through three pillars: vaccination, education and surveillance. We're collaborating with governmental and non-governmental organizations, health authorities, veterinarians, local communities, dog owners, and other partners, to Stop Rabies before it starts. Judith's story is a powerful reminder of why preventable diseases like rabies must be eliminated and how collaborative action can help save lives. Find out more and explore other stories on Imagine: our sustainability story hub, where we share our commitment to sustainability and what we are doing to create a positive impact for humans, animals and our planet.
Yahoo
2 days ago
- Business
- Yahoo
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young (EY), then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance. 'It is with great enthusiasm that I join the Virbac group and prepare to discover the exciting world of animal health. I look forward to working with Virbac's exceptional teams to continue building the future on the strong existing foundations, innovating, and creating a positive and lasting impact for animals, their owners, and veterinarians worldwide', Paul Martingell announced. Marie-Hélène Dick, chairwoman of the board of directors of Virbac, stated: ''with his impressive background, energy, benevolent leadership, human approach, proven experience in the consumer health sector, international culture, and ability to embrace new challenges, the board of directors believes that Paul Martingell will be able to guide the Virbac teams and contribute to the long-term development of the Group by bringing a new perspective.' On June 18, 2025, the Virbac board of directors, upon recommendation from the appointments and compensation committee, appointed Paul Martingell as chief executive officer, effective September 1, 2025. The board of directors extends its gratitude to Habib Ramdani for diligently and professionally serving as interim chief executive officer. About Virbac - Caring for animals together At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together. Press contacts - Agence Libremullenlowe Julie Adam - - + 33 7 86 82 60 61 Melina Constantinidis - - +33 7 63 18 97 34 Attachment Virbac PR - new CEO
